Hyperfine Inc stock (US44917L1098): NASDAQ listing stays active

Hyperfine Inc is still trading on Nasdaq, which keeps the U.S. medtech stock in the active-listing category on 06/03/2026. Benzinga's Hyperfine corporate event calendar shows scheduled company activity for the NASDAQ-listed name, while the issuer's investor-relations site remains the primary reference point for company updates.

The stock traded on Nasdaq under HYPR, with the company identified by ISIN US44917L1098. For investors following the U.S. market, the relevant home-country frame is the Nasdaq listing itself, and the current setup appears to center on product execution and event-driven trading rather than any confirmed take-private process.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

Hyperfine Inc: core business model

Hyperfine develops portable magnetic resonance imaging systems for clinical use, with its revenue tied primarily to system placements, disposables, and service activity around the installed base.

Hyperfine Inc in peer comparison

In the portable and compact imaging niche, Hyperfine is still positioned as a smaller-cap U.S. medtech name alongside broader imaging groups such as GE HealthCare, Siemens Healthineers, and Koninklijke Philips, but each of those peers operates at a much larger scale and with a wider product mix.

That relative scale matters because the market often values Hyperfine on execution milestones, regulatory progress, and adoption pace rather than on the mature cash-generation profile seen in larger diversified imaging franchises.

For U.S. investors, the Nasdaq listing remains the key domestic reference point, and no positive evidence of a completed delisting or take-private was identified in the sources reviewed.

Conclusion

Today's key point is simple: Hyperfine remains an actively listed Nasdaq stock, and the available June 2026 source material points to continued event-driven interest rather than a completed corporate exit. In peer terms, the company still trades as a smaller standalone medtech name, so any new catalyst is likely to matter more for sentiment than for sector-wide scale comparisons.

The next stock-specific move will probably hinge on company disclosures, event calendar updates, or operating news from investor relations, which can shift attention quickly in a thinly followed name.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.